Clinical Trial Update: Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) [Phase 3]

View source ↗

Summary

Phase 3 trial of prasterone (DHEA) for hypoactive sexual desire disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• Prasterone (dehydroepiandrosterone (DHEA))

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Hypoactive Sexual Desire Disorder | Phase 3 | Status: COMPLETED